Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trialJunichi Nishimura, Masaki Mori, Mamoru Uemura et al.|European Journal of Cancer|2015Cited by 75
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter TrialHirofumi Yamamoto, Masaki Mori, Kohei Murata et al.|Clinical Cancer Research|2016Cited by 43
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.Shigeyoshi Iwamoto, Hideyuki Mishima, Shoichi Hazama et al.|PubMed|2014Cited by 22
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study)Toshikazu Moriwaki, Ichinosuke Hyodo, Hideaki Bando et al.|Medical Oncology|2011Cited by 19
Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancerYoshinori Munemoto, Hideyuki Mishima, Mitsuro Kanda et al.|BMC Cancer|2015Cited by 18